Physicians

Department / Division
Medicine / Med - Endocrinology & Metab

Address
DUMC 3470
Durham, NC 27710

Appointment Telephone
919-668-7630

Office Telephone
919-668-1367

Fax Telephone
919-668-1366

Training

• MD, University of Chicago Pritzker School of Medicine (Illinois), 1989

Residency

• Internal Medicine, Yale-New Haven Hospital (Connecticut), 1989-1992
• Endocrinology and Metabolism, Duke University Medical Center, 1993-1997

Clinical Interests
Osteoporosis and metabolic bone disease including male osteoporosis, transplantation osteoporosis, male hypogonadism; secondary osteoporosis including glucocorticoid induced, familial and acquired hypophosphatemic disorders

Research Interests
Osteoporosis, with current studies that focus on advances in diagnosis and natural history of male and postmenopausal osteoporosis. The study on male osteoporosis include a collaborative study with outside investigators is examining the utility of lateral spine bone densitometry in identifying men with osteoporosis and low trauma fractures.

Hypophosphatemic disorders, including X-link hypophosphatemic rickets and tumor-induced osteomalacia. My ongoing research study, in collaboration with Dr. L Darryl Quarles at the University of Kansas, seeks to further confirm and extend our understanding of the role of FGF-23 in human disorders of phosphate homeostasis, including patients with chronic kidney disease. Pending studies include primary and sub-investigator directed Phase 1 / 2 first in human studies examining the effects of a monoclonal antibody and enzyme replacement therapy for X-linked hypophosphatemic rickets and hypophosphatasia, respectively.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Amgen, Inc.
• Auxilium Pharmaceuticals, Inc.
• Eli Lilly & Co.
• Kyowa
• Novartis
• Roche

Representative Publications
Case LE, Hanna R, Frush DP, Krishnamurthy V, DeArmey S, Mackey J, Boney A, Morgan C, Corzo D, Bouchard S, Weber TJ, Chen YT, Kishnani PS. Fractures in children with Pompe disease: a potential long-term complication. Pediatr Radiol. 2007 May;37(5):437-45. (2007) Abstract

Gold DT, Weber TJ. Update on Male Osteoporosis. Adv Stud Med: 6(4):171-181, 2006. (2006)

Wang C, Swerdloff, R, Cunningham, G, Dobs, A, Iranmanesh, A, Matsumoto, A, Synder, P, Weber, T, Berman, N, Hull L and the Testosterone Gel Study Group. Long-term testosterone gel (AndroGel ) treatment for maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 89:2085-98, 2004. (2004)

Weber TJ, Liu S, Indridason OS, Quarles LD. Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res. 2003 Jul;18(7):1227-34. (2003) Abstract

Weber TJ, Drezner MK. Effect of alendronate on bone mineral density in male idiopathic osteoporosis. Metabolism. 2001 Aug;50(8):912-5. (2001) Abstract